Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 18, 2026JACC Case ReportsOpen Access

Rilonacept induces clinical remission in a recurrent pericarditis case with rapid response to post-relapse reinitiation.

View Full Paper
Ask AI
Bookmark
Share

Population

1 26-year-old female rugby player with recurrent pericarditis after atrial septal defect repair

Design

Case_report

Follow-up

11 months (time to relapse after tapering)

Key result

Rilonacept induced clinical remission in a 26-year-old athlete with recurrent pericarditis, who relapsed 11 months after tapering but responded rapidly to reinitiation.

Authors

AAAbdallah AbuawadOBOsamah BadwanMEMuhammad Ehsan

Discussion

Loading...

Member takes

Overview

Suggests rilonacept re-challenge after relapse in recurrent pericarditis; hypothesis-generating and requires prospective trials.

Key Points

  • This case aims to explore the complexities of managing recurrent pericarditis in a young athlete and the implications for return to play.
  • Monitored a 26-year-old rugby player with recurrent pericarditis post-atrial septal defect repair.
  • Utilized cardiac magnetic resonance (CMR) imaging and inflammatory biomarker assessments for evaluation.
  • Implemented rilonacept therapy with a gradual taper while observing clinical and imaging changes.
  • Initial treatment with rilonacept led to clinical remission, noted by normal biomarkers and symptom absence.
  • Relapse occurred after tapering off rilonacept, but the athlete responded quickly upon treatment reinitiation.
  • Serial CMR and risk scores provided valuable context for managing tapering decisions and individual care.

Study Design

Type

Case Report (n=1)

Structured PICO

P
Population
A 26-year-old female rugby player with recurrent pericarditis after atrial septal defect repair.
I
Intervention
Rilonacept (initiation, tapering, and reinitiation)
O
Outcome
Clinical remission, relapse, and response to reinitiation

This case demonstrates the complexity of managing recurrent pericarditis in athletes and suggests serial CMR and clinical risk scores may provide context for cautious tapering of rilonacept.

Limitations

  • Evidence remains limited regarding the use of serial CMR and clinical risk scores for cautious tapering
  • evidence remains limited

Cite This Study

Abuawad et al. (2026) conducted a case report in Recurrent pericarditis (n=1). Rilonacept was evaluated on Clinical remission and relapse. Rilonacept induced clinical remission in a 26-year-old athlete with recurrent pericarditis, who relapsed 11 months after tapering but responded rapidly to reinitiation.

synapsesocial.com/papers/6a5b38f68167787360d24dd0https://doi.org/10.1016/j.jaccas.2026.108804
View Full Paper
Ask AI
Bookmark
Share